510(k) Report

510(k) · Cleared

Cleared

Architect Ivancomycin

K123947510(k) TraditionalCleared Aug 29, 2013251-day reviewClass II21 CFR 862.3950

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Biokit, S.A. · LEH Radioimmunoassay, Vancomycin

Cleared on Aug 29, 2013 as substantially equivalent to K072036 (Biokit, S.A., 2008) after a 251-day review. Its family tree reaches back 2 generations to 1996.

Decided
Aug 29, 2013
Review
251 days
Class
Class II
Product code
LEH
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to K955851 (1996). No later device cites it as a predicate yet.

  1. Root · 2 generations backK955851 Axsym Vancomycin IIAbbott Laboratories · 1996
  2. 1 generation backK072036 Architect Ivancomycin Reagents and Architect Ivancomycin…Biokit, S.A. · 2008 · Recalled
  3. This deviceK123947 Architect IvancomycinBiokit, S.A. · 2013
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K955851Axsym Vancomycin IIAbbott Laboratories1996—
−1K072036Architect Ivancomycin Reagents and Architect Ivancomycin Calibrators, Models…Biokit, S.A.20081
0 (this device)K123947Architect IvancomycinBiokit, S.A.2013—
FIG. 1 — Lineage of K123947, 1996–2013Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LEH? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new LEH device

  1. #1 K222439 Atellica® CH Phencyclidine (Pcp), Atellica® CH…score 7.0 · 5 generations · no Class I recall
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K072036Architect Ivancomycin Reagents and Architect Ivancomycin Calibrators, Models: 1P30-25…
Summary page 1
…Equivalency is Claimed The ARCHITECT i Vancomycin assay (LN I1P30-28) is substantially equivalent to the previously cleared ARCHITECT i Vancomycin assay (LN 1P30-25, K072036). 510(k) Summary Page I Ors…
Biokit, S.A.20081

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 17 years and passes through 2 companies; a new generation was cleared every 11.9 years on median.
  • 1 of the 2 ancestors has a recall of any class.

How does its category compare?

All LEH devices

LEH Radioimmunoassay, Vancomycin: FDA decisions, review times, recalls and adverse event reports over 20 years. 2013, this device’s year, is highlighted.

FDA decisions per year · LEH

1in 2023

2008: 12013: 12016: 22023: 1
2007high 2 (2016) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LEH

Too few LEH 510(k)s in any year since 2007 to give a median.

Recalls per year · LEH

2in 2019

2007: 22019: 2
2007high 2 (2007) · low 0 (2008)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · LEH

14in 2025

2007: 42008: 122009: 252010: 482011: 552012: 802013: 732014: 402015: 262016: 102017: 152018: 172019: 132020: 142021: 112022: 72023: 112024: 142025: 14
2007high 80 (2012) · low 4 (2007)2025

MAUDE reports naming product code LEH, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—24
20081—012
20090—025
20100—048
20110—055
20120—080
20131—073
20140—040
20150—026
20162—010
20170—015
20180—017
20190—213
20200—014
20210—011
20220—07
20231—011
20240—014
20250—014
20260—0—

What is it indicated for?

The ARCHITECT i Vancomycin assay is an in vitro chemiluminescent microparticle immunoassay (CMIA) for the quantitative measurement of vancomycin in human serum or plasma on the ARCHITECT i System with STAT protocol capability. The ARCHITECT i Vancomycin assay is used in the diagnosis and treatment of vancomycin overdose and in monitoring levels of vancomycin to help ensure appropriate therapy.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K123947: Architect Ivancomycin.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K123947

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026